Teva Wins Ban On Mylan Parkinson's Generic

Law360, New York (December 16, 2013, 6:40 PM EST) -- A New Jersey federal judge on Friday barred  Mylan Inc. from manufacturing, importing or selling its own version of Teva Pharmaceutical Industries Ltd.'s brand-name treatment for Parkinson's disease, Azilect, for more than three years, after the generic-drug maker stipulated its proposed generic infringed a Teva patent.

U.S. District Judge Claire C. Cecchi embraced the injunction that Teva had been calling for, after the two pharmaceutical manufacturers disputed what form the court's final judgment should take, with Mylan advocating for an order that would only stop it...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.